Myriad Genetic Laboratories
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Myriad Genetic Laboratories sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Myriad Genetic Laboratories: 15 sponsored US clinical trials, none currently recruiting.
Myriad Genetic Laboratories sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 3 trials.
Top-decile sponsor footprint
Myriad Genetic Laboratories ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894
EndoPredict® Extended Endocrine Trial (EXET)
NCT04016935
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing
NCT04015102
Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing
NCT03511235
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
NCT03290508
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes
NCT03081455
Bipolar Proteomic Assay Validation Study
NCT02746367
Combined Breast Cancer Risk Study
NCT03067389
Prospective Prolaris Value and Efficacy
NCT03152448
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
NCT02121899
Registry to Measure the Impact of Adding Genomic Testing
NCT02454595
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
NCT02209584
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
NCT02121925
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
NCT01954004
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6
NCT01468623
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
How the Myriad Genetic Laboratories archive is shaped
15 indexed studies, none listed as recruiting (0% open); 7 completed (47%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Prostate Cancer (3 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Myriad Genetic Laboratories: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Myriad Genetic Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Myriad Genetic Laboratories page
15 registered trials is a research-attention snapshot, not an endorsement of Myriad Genetic Laboratories or any single study.
- None of Myriad Genetic Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prostate Cancer is the condition Myriad Genetic Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Myriad Genetic Laboratories pipeline card: 15 registered trials from official public datasets.Report a data error.